Daicel Corporation (4202)

Name: Daicel Corporation (4202) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Basic Materials · Wall Street (USA) · Ultimo aggiornamento: 2026-10-02

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services.

Dati chiave

Capitalizzazione di mercato: JPY 359 billion
Ricavi (esercizio chiuso a 2026-03-31): JPY 579.6B
Utile netto: JPY 10.2B
Margine lordo: 25.2%
Margine netto: 1.8%

Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Entrate totali	JPY 579.6B	JPY 586.5B	JPY 558.1B	JPY 538.0B
Utile lordo	JPY 146.3B	JPY 164.7B	JPY 159.3B	JPY 145.8B
Risultato Operativo (EBIT)	JPY 42.1B	JPY 61.0B	JPY 62.4B	JPY 47.5B
Reddito netto	JPY 10.2B	JPY 49.5B	JPY 55.8B	JPY 40.7B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di 4202. /companies/us/4202

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.